Filing Flows

Filing Flows › Lifecore Biomedical (LFCR) › How it makes money

How Lifecore Biomedical (LFCR) makes money

Lifecore Biomedical (LFCR) made $25.3M of revenue in the first quarter fiscal 2027 (Q1 FY27), -19% from a year earlier. CDMO brought in $17.8M (70%); HA manufacturing brought in $7.5M (30%).

Drawing the Sankey…

Lifecore Biomedical revenue by segment, Q1 FY27Lifecore Biomedical revenue by segment, Q1 FY27CDMO$17.8MHA manufacturing$7.5M
Lifecore Biomedical: revenue by line, Q2 FY25 to Q1 FY27Lifecore Biomedical: revenue by line, Q2 FY25 to Q1 FY27CDMOHA manufacturingCDMO: $17.8M latest$17.8MHA manufacturing: $7.5M latest$7.5MQ2 FY25Q3 FY25Q4 FY25Q1 FY26Q3 FY26Q1 FY27Q1 FY27
CDMO went from 79% of revenue in Q2 FY25 to 70% in Q1 FY27, the largest shift in the mix.
Lifecore Biomedical revenue by quarterLifecore Biomedical revenue by quarter$32.6MQ2 FY25$35.2MQ3 FY25$36.4MQ4 FY25$31.1MQ1 FY26$23.2MQ3 FY26$34.2MQ1 FY27$25.3MQ1 FY27
Lifecore Biomedical: where each dollar of revenue goesLifecore Biomedical: where each dollar of revenue goesIncome tax0¢Operating cash flow27¢Free cash flow24¢

Revenue by segment, Q1 FY27

SegmentRevenueShareQ/QY/Y
CDMO$17.8M70.2%+14%-18%
HA manufacturing$7.5M29.8%-59%-19%

Where each dollar of revenue goes

LineQ1 FY27% of revenue
Revenue$25.3M100.0%
Income tax$51K0.2%
Operating cash flow$6.9M27.4%
Free cash flow$6.0M23.8%

Revenue, quarter by quarter

QuarterRevenueY/Y
Q1 FY27$25.3M-19%
Q1 FY27$34.2M—
Q3 FY26$23.2M—
Q1 FY26$31.1M—
Q4 FY25$36.4M-4%
Q3 FY25$35.2M-2%
Q2 FY25$32.6M+8%

From Lifecore Biomedical's 10-Q filed Nov 4, 2026 (on EDGAR).

Questions

How does Lifecore Biomedical make money?

Lifecore Biomedical (LFCR) made $25.3M of revenue in the first quarter fiscal 2027 (Q1 FY27), -19% from a year earlier. CDMO brought in $17.8M (70%); HA manufacturing brought in $7.5M (30%).

What is Lifecore Biomedical's biggest business?

CDMO: $17.8M in the first quarter fiscal 2027, 70% of revenue, -18% from a year earlier.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.